Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B study of pegbelfermin in NASH with compensated cirrhosis
jRCT2080223974Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Pegbelfermin with Placebo (2 arms). Started Jul 2018; status: completed.
02
Drugs
pegbelfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on jRCT2080223974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223974.